Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 757

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 757
---
. See Item 5. “Operating and Financial Review and Prospects — Recent Financing Agreements” for more information about this document. •Securities Purchase Agreement, dated December6, 2022 by and between NLS Pharmaceutics Ltd. and funds affiliated with BVF Partners L.P., or collectively, BVF. See Item 5. “Operating and Financial Review and Prospects — Recent Financing Agreements” for more information about this document. •Short Term Loan Agreement, dated September28, 2023 by and between NLS Pharmaceutics Ltd., and Ronald Hafner. See Item 5. “Operating and Financial Review and Prospects — Recent Financing Agreements” for more information about this document. •Short Term Loan Agreements, dated November15, 2023, by and between NLS Pharmaceutics Ltd., and certain existing shareholders of the Company, including Ronald Hafner, the Company’s Chairman of the Board of Directors, Felix Grisard, Jürgen Bauer and Maria Nayvalt. See Item 5. “Operating and Financial Review and Prospects — Recent Financing Agreements” for more information about this document. •License Agreement, dated March19, 2024, by and between NLS Pharmaceutics Ltd. and Aexon Labs, Inc., a Delaware corporation. See Item 4. “Business Overview — Additional Pre -ClinicalCompounds” for more information about this document. D. Exchange Controls There are no Swiss governmental laws, decrees or regulations that restrict, in a manner material to us, the export or import of capital, including any foreign exchange controls, or that generally affect the remittance of dividends or other payments to non -residentsor non -citizensof Switzerland who hold our common shares. E. Taxation. Switzerland Tax Consideration This summary of material Swiss tax consequences is based on Swiss law and regulations and the practice of the Swiss tax administration as in effect on the date hereof, all of which are subject to change (or subject to changes in interpretation), possibly with retroactive effect. The summary does not purport to take into account the specific circumstances of any particular shareholder or potential investor and does not relate to persons in the business Annex F-95 of buying and selling common shares or other securities. The summary is not intended to be, and should not be interpreted as, legal or tax advice to any particular potential shareholder/s, and no representation with respect to the tax consequences to any particular shareholder/s is made. Current